Back to Trial

Oracle Runs

Oracle findings and outcome history for A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme (NCT04762069).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 6:49 PM
Resolution Evidence
Outcome
NO
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

Public readout was negative for this Phase 2 trial: the sponsor said the primary analysis did not show a statistically significant overall-survival benefit, and later described the study as not meeting its primary target. Comparable secondary/clinical observations do not override the failed primary endpoint.

Sources
Sponsorcnspharma.com3/25/25
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

Sponsor: Berubicin showed outcomes comparable to lomustine on multiple measures, but the analysis did not demonstrate statistically significant superiority in overall survival, the primary endpoint.

View source
Sponsoraccessnewswire.com3/31/25
CNS Pharmaceuticals Reports Full Year 2024 Financial Results

Company update: the Berubicin study did not meet its primary target; management said it yielded insight on safety/activity but is preparing regulatory discussions on the program’s future.

View source
Web Searchsec.gov11/27/25
CNS Pharmaceuticals Combined Form 10-K and 10-KA 12-31-24

SEC filing states topline data showed Berubicin had clinically relevant outcomes that appeared comparable to lomustine, but it did not demonstrate a statistically significant difference in overall survival, the primary endpoint.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NOAccepted94% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Public readout was negative for this Phase 2 trial: the sponsor said the primary analysis did not show a statistically significant overall-survival benefit, and later described the study as not meeting its primary target. Comparable secondary/clinical observations do not override the failed primary endpoint.

Found Apr 1, 2026, 6:49 PMOutcome date Mar 25, 2025, 12:00 AMReviewed Apr 1, 2026, 7:04 PM
Sponsorcnspharma.comMar 25, 2025, 12:00 AM
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
Sponsor: Berubicin showed outcomes comparable to lomustine on multiple measures, but the analysis did not demonstrate statistically significant superiority in overall survival, the primary endpoint.
Sponsoraccessnewswire.comMar 31, 2025, 12:00 AM
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
Company update: the Berubicin study did not meet its primary target; management said it yielded insight on safety/activity but is preparing regulatory discussions on the program’s future.
Web Searchsec.govNov 27, 2025, 12:00 AM
CNS Pharmaceuticals Combined Form 10-K and 10-KA 12-31-24
SEC filing states topline data showed Berubicin had clinically relevant outcomes that appeared comparable to lomustine, but it did not demonstrate a statistically significant difference in overall survival, the primary endpoint.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 7:04 PM

Will the results be positive?

PendingtoNOcurrentNO
GPT-5.4 (OpenAI)94% confidenceReviewed Apr 1, 2026, 7:04 PM

Public readout was negative for this Phase 2 trial: the sponsor said the primary analysis did not show a statistically significant overall-survival benefit, and later described the study as not meeting its primary target. Comparable secondary/clinical observations do not override the failed primary endpoint.